-
Abbott's Phase IIb data provide the most compelling argument to date that all-oral HCV cocktails do not require a nucleotide-based NS5B inhibitor for clinical success.
Published on 10/22/2012
-
Nuclear pacifism Cracking the combination New Phase II data show interferon-free combinations of HCV therapeutics being developed by Abbott Laboratories (NYSE:ABT) and Bristol-Myers Squibb Co. (NYSE:BMY) could …
Published on 10/22/2012
-
Nuclear pacifism HCV toolkit At least nine companies have clinical-stage HCV compounds with two or more direct-acting antiviral mechanisms of action. New data have shown SVR rates >90% for combinations built around …
Published on 10/22/2012
-
Ardelyx took its gut-specific small molecule approach from concept to Phase II in under four years and now has scored a partnership with AstraZeneca as the pharma moves into diabetic complications.
Published on 10/15/2012
-
XenoPort is seeking to build a better version of the most hotly anticipated MS compound in years - Biogen Idec's BG-12 - with a novel prodrug that could offer once-a-day dosing and fewer side effects.
Published on 10/15/2012
-
Contrarian thinking Roche/Genentech CNS pipeline Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit have disclosed 11 compounds in clinical development for CNS diseases. Through Phase II, molecules are …
Published on 10/8/2012
-
Edison leveraged insights from an expanded access protocol to score a positive Phase IIa result for EPI-743 in Leigh disease, and now plans to move into Phase IIb in both Leigh and Freidrich's ataxia.
Published on 10/8/2012
-
Efficacy and MOA are behind Opexa's decision to focus MS cell therapy Tcelna on secondary progressive disease instead of relapsing-remitting disease.
Published on 10/8/2012
-
Even as many drug companies flee neuroscience, Roche and Genentech are building R&D and deals in CNS based on advances in genetics and imaging, plus a better understanding of disease mechanisms.
Published on 10/8/2012
-
Genzyme believes the safety and tolerability will give its oral MS drug a leg up over injectables. But some doctors say pregnancy restrictions, efficacy and Biogen Idec's BG-12 will relegate it to niche use.
Published on 10/1/2012
-
Ten pharma companies have created TransCelerate, a not-for-profit for drug developers to solve clinical trial bottlenecks. It hopes to have results from the first five projects within a year.
Published on 10/1/2012
-
Excited about cycling Building cycles At least 12 companies are developing macrocycle and constrained-peptide synthesis technologies. (A) Disclosed financings; (B) Formed following the merger of Tranzyme Inc. with …
Published on 9/17/2012
-
Excited about cycling Cycle shops At least 27 corporate drug development partnerships using macrocycle technologies and constrained peptide technologies have been announced since 2007, with several pharmas sampling …
Published on 9/17/2012
-
The explosion of biopharma interest in macrocycles and constrained peptides is driven by new synthesis and screening technology and, if cell permeability can be solved, the allure of access to undruggable targets.
Published on 9/17/2012
-
Increased rates of interstitial lung disease led partner Kyowa to suspend a Phase III trial of tivantinib for NSCLC, but ArQule believes the phenomenon is specific to the Japanese population.
Published on 9/10/2012
-
Bristol-Myers is not discussing why it thought a therapeutic window for BMS-986904 could be found, but early red flags suggest more robust in vitro testing could have made the HCV compound's cardiotoxicity more apparent…
Published on 9/10/2012
-
With positive Phase IIb data in hand for atherosclerosis candidate RVX-208, Resverlogix is looking to data next half from another Phase IIb trial to show longer term dosing actually removes plaque.
Published on 9/10/2012
-
After 20 years, Marqibo vincristine won accelerated approval from FDA after Talon applied the lessons from a previous rejection by conducting a more thoroughly adjudicated study in a new cancer setting.
Published on 8/20/2012
-
The University of Pennsylvania's targeted T cell therapy could have advantages over other immunotherapies, and POC in three patients was enough to convince Novartis.
Published on 8/13/2012
-
EnVivo's EVP-6124 is the first CHRNA7 agonist to show positive results in Phase II trials in two CNS indications -- schizophrenia and now Alzheimer's.
Published on 7/30/2012
-
Debiopharm has been stocking up on early stage cancer assets. The latest is a dual VEGFR-2/c-Met inhibitor from Ascepion that Debiopharm thinks has best-in-class potential.
Published on 7/23/2012
-
Odanacatib was deemed 'robust' in a Phase III trial for postmenopausal osteoporosis, but final safety and fracture data will dictate if the cathepsin K inhibitor can jump to the front of the line after bisphosphonates.
Published on 7/23/2012
-
Acacia hoped APD421 would be as efficacious as droperidol in PONV while providing a safety advantage. Now Phase II data show it actually may also have an efficacy advantage over other anti-emetics.
Published on 6/18/2012
-
Immune springboard Checkpoint inhibitor pipeline Selected checkpoint inhibitors in clinical testing for various cancers. Source: BCIQ: BioCentury Online Intelligence; company press releases; www.clinicaltrials.gov …
Published on 6/18/2012
-
Immune springboard Late-stage cancer vaccines Selected cancer vaccines in Phase III testing, sorted by milestone date. (A) Trial completion indicates final data collection date for primary endpoint; Source: BCIQ: …
Published on 6/18/2012